Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus TAVIST ALLERGY SINUS HEADACHE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus TAVIST ALLERGY SINUS HEADACHE.
KETOTIFEN FUMARATE vs TAVIST ALLERGY/SINUS/HEADACHE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
TAVIST ALLERGY/SINUS/HEADACHE contains clemastine fumarate (first-generation antihistamine) that competitively antagonizes histamine at H1 receptors, and acetaminophen that inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and fever; phenylpropanolamine is an alpha-adrenergic agonist that causes vasoconstriction of nasal mucosa.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
1 tablet (acetaminophen 500 mg, diphenhydramine 12.5 mg, phenylephrine 10 mg) orally every 4-6 hours as needed; maximum 4 tablets per day
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
5-7 hours for clemastine; 12-15 hours for pseudoephedrine; acetaminophen half-life 2-3 hours. Context: Clemastine half-life supports twice-daily dosing; pseudoephedrine's longer half-life allows 6-8 hour dosing intervals
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal excretion of unchanged drug and metabolites accounts for 70-80%, with 15-25% fecal elimination; bilary excretion contributes to remaining
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine/Decongestant Combination